Skip to main content
. 2015 Jun 29;5:11736. doi: 10.1038/srep11736

Figure 1. BST-2 effectively restricts HBV surface antigen release in 293T cells.

Figure 1

(a) 293T cells were co-transfected with 0, 25, 50, or 100 ng of BST-2 IHA WT or delGPI plasmid along with 1 μg of HBV plasmid. BST-2 IHA was detected by Western blotting, and tubulin was used as a loading control. (b) HBV antigens in the cells and supernatants (sup) of a) were detected by ELISA. HBsAg release percentages are shown in columns. (c) 293T cells were transfected with 1 μg of HBV plasmid along with the control or BST-2 siRNA, followed by a treatment of 1000 U/ml IFN-α 24 h post-transfection. After another 48 h, BST-2 was detected with BST-2 antibody by Western blotting. (d) HBV antigen expression and release of c) were examined with ELISA, and HBsAg release percentages are shown in columns. (e) 293T cells were co-transfected with 1 μg of HBV construct, along with 50 ng of BST-2 variant. BST-2 IHA and tubulin were examined by Western blotting. (f) HBV antigen expression and release of e) were examined by ELISA. (g) 293T cells were co-transfected with 1 μg of pNL4-3 ΔVpu, along with 50 ng of BST-2 variant. BST-2 IHA, tubulin, cellular Gag, and released capsid were detected by Western blotting. (h) The HBsAg release in f) and the titration of the released infectious HIV-1 viruses in g) are shown with percentages. **P < 0.01, *P < 0.05. These experiments were performed no less than three times, all with similar results.